8 research outputs found

    Study on Marine Microbial Community, Respiration Rate and Controlled Factors

    Get PDF
    海洋在全球气候变化中扮演着举足轻重的作用,具有吸收和储藏CO2的能力,对海洋碳循环的研究已经成为当今的热点。微型浮游生物在海洋呼吸作用中发挥了很大的作用,且主要通过代谢活动实现碳在海洋生态系统中循环。呼吸作用代表着海洋中有机物的消耗及循环流通,对于有机碳在沉积物中的积累,或者输出到大气中的CO2的量是十分重要的,这对于衡量生态系统中碳收支平衡必不可少。因此,海洋微型生物呼吸作用的研究为我们更好地了解海洋生态系统的碳通量提供了依据。微生物呼吸速率的研究已经在迅速发展,同时环境因素对原核生物呼吸速率的影响也得到了一定的证实。但由于测定方法的不同及不同水体生态系统中呼吸速率对环境因子响应存在差异,这...The ocean plays an important role in global climate change, with the ability to absorb and store CO2. The ocean carbon cycle has captured our attention. Marine heterotrophic bacteria play a very important role in ocean carbon cycle with their metabolism activities. The respiration represents the consumption or flux of organic matter in the oceans, which is important for the accumulation of organic...学位:理学硕士院系专业:海洋与地球学院_海洋生物技术学号:2232013115145

    Clinical efficacy of the fine needle aspiration of the cell block in the diagnosis of parotid gland masses

    Get PDF
    目的探讨超声引导下细针穿刺制作细胞块在诊断腮腺区肿块方面的应用价值。方法在彩色超声仪引导下,对285个腮腺区肿块进行细针穿刺,将穿刺标本制成细胞块,以进行病理学诊断。对非肿瘤性肿块采取保守治疗,囊肿与肿瘤性肿块采取手术治疗。对术后病理确诊为腺样囊性癌(ACC)与多形性腺瘤(PA)对应的细胞块行干细胞因子受体CD117免疫组织化学检测。结果标本制作满意率为95.1%(271/285),诊断准确率为94.5%(256/271);诊断敏感度为87.0%(67/77),特异度为98.1%(157/160)。CD117在ACC中的阳性表达率为95.2%(20/21),在PA中为20.3%(25/123),ACC中阳性表达率明显高于PA,二者差异有统计学意义(P<0.01)。结论超声引导下腮腺区肿块细针穿刺制作细胞块结合分子标志物检测,对腮腺区肿块的诊断具有重要意义。Objective To investigate the clinical significance of cell blocks obtained by ultrasound-guided fine needle aspiration in diagnosing parotid gland masses. Methods Cell blocks were made in 285 parotid gland masses by ultrasoundguided fine needle aspiration. Diagnosis was conducted using the cell blocks. Non-tumor masses were subjected to conservative treatment, and cysts and tumors were treated with surgery. The cell block sections from masses with the diagnosis of adenoid cystic carcinoma(ACC) and pleomorphic adenoma(PA) were applied to the detection of immunocytochemical staining for the stem cell factor receptor CD117. Results The satisfaction rate of the specimen was 95.1%(271/285). The accuracy rate of the diagnosis was 94.5%(256/271), the sensitivity was 87.0%(67/77), and the specificity was 98.1%(157/160). The positive rate of CD117 in ACC was 95.2%(20/21), whereas that in PA was 20.3%(25/123). The positive rate of CD117 in ACC was higher than that in PA(P<0.01). Conclusion The use of cell blocks obtained from ultrasound-guided fine needle aspiration, together with molecular marker detection, has great significance in diagnosing parotid gland masses

    Mercury ion detection reagent and detection method

    No full text
    本发明公开了一种汞离子检测试剂及检测方法,该试剂包括纳米溶胶、拉曼活性分子标记的核酸适配体和电荷修饰剂;其检测方法是先合成纳米溶胶,再向适量新鲜纳米溶胶中加入适量适配体,并混合均匀;继续加入适量电荷修饰剂,并混合均匀;然后加入待测样品,孵育1-5分钟.最后取上述纳米溶胶,测试拉曼散射光谱信号,并进行数据处理。本发明基于Hg2+加入致使纳米粒子表面核酸适配体的结构变化,即银溶胶中纳米粒子聚集和信号分子的表面增强拉曼散射信号增强。本发明采用SERS分析技术,对Hg2+检出限在nmol/L水平,对Hg2+浓度的线性响应范围快,同时具有高选择性,适于环境水中痕量Hg2+的快速检测

    大连极紫外相干光源

    No full text
    先进光源的发展在前沿科学研究中发挥的作用越来越重要。近十年来,飞速发展的自由电子激光技术为科学家们提供了探索未知世界、发现新科学规律和实现技术变革的重要工具。建成的大连极紫外(EUV)相干光源的运行波段为50~150nm,单脉冲能量大于100μJ,且可提供10-12 s和10-13 s量级的超快激光脉冲,是我国第一台自由电子激光用户装置,并且是国际上唯一运行在极紫外波段的自由电子激光用户装置,在世界范围内为用户提供具有高峰值亮度和超短脉冲的极紫外激光。大连EUV相干光源是由国家自然科学基金委资助、由中国科学院大连化学物理研究所和上海应用物理研究所共同承担的重大科学仪器研制项目,目标是打造一个以先进极紫外光源为核心、主要用于能源基础科学研究的光子科学平台

    Aripiprazole versus other atypical antipsychotics for schizophrenia

    No full text
    BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials

    Ziprasidone versus other atypical antipsychotics for schizophrenia

    No full text
    corecore